# J&J Says Phase 4 Data Showed Tremfya Reduced Pain and Stiffness

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/62101
Published: 2026-11-20T14:09:04.000Z
Updated: 2026-11-20T14:09:04.000Z
Section: Business

> The findings involved patients with psoriatic arthritis and axial involvement, with reductions reported at week 24.

Johnson & Johnson said Phase 4 data showed Tremfya led to reductions in pain, stiffness, swelling and fatigue among patients with psoriatic arthritis and axial involvement, with findings reported at week 24.

Tremfya, also known as guselkumab, is an interleukin-23 antagonist.


